Evaluation of inflammation markers and their association with clinical features in patients with Metabolic Syndrome and Type 2 Diabetes Mellitus
Author :
Abstract
Keywords
Abstract
OBJECTIVE: The aim of this study was to evaluate inflammation markers in patients with metabolic
syndrome (MetS) and Type 2 Diabetes Mellitus (DM), and to investigate potential relationships
between these parameters and other clinical and laboratory properties of patients.
METHODS: This study was conducted at Haseki Training and Research Hospital. The study group
consisted of 60 patients diagnosed with MetS and/or Type 2 DM and 20 healthy individuals. MetS
was diagnosed with the National Cholesterol Education Program - Adult Treatment Panel III diagnostic
criteria. A broad range of parameters and clinical characteristics were measured and recorded,
including vitals, anthropometric parameters, hepatosteatosis, microalbuminuria, C-reactive protein
(CRP), fibrinogen, interleukinn-6 (IL-6), tumor necrosis factor-α (TNF-α), microalbuminuria in 24-hour
urine, abdominal ultrasonography and routine biochemistry tests.
RESULTS: As anticipated, anthropometric measures, liver function tests and lipid profiles
demonstrated higher levels among patients with MetS/type 2 DM compared to healthy subjects.
Almost all inflammation markers were also elevated, evidencing the elevated baseline inflammatory
activity among patients compared to healthy controls. The prevalence of hepatosteatosis (as a
precursor to non-alcoholic fatty liver disease) was 51.7% among patients with MetS in the study group.
Waist-to-hip ratio (p=0.012), ALT (p<0.001) and AST (P<0.001) values were higher in subjects with
hepatosteatosis. The prevalence of microalbuminuria was 38.3% and these patients had significantly
higher diastolic and systolic blood pressure values (p=0.005 and p=0.002, respectively).
CONCLUSIONS: In conclusion, patients with Type 2 DM and MetS have significantly elevated
inflammatory markers and a high frequency of hepatosteatosis and microalbuminuria which appear to
be associated with different clinical characteristics. More comprehensive prospective studies with Type
2 DM and MetS patients are needed
